专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110229571A1 Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker 审中-公开
标题翻译：包含选择性I1咪唑啉受体激动剂和血管紧张素II受体阻断剂的药物组合物
公开(公告)号：US20110229571A1
公开(公告)日：2011-09-22
申请号：US13116620
申请日：2011-05-26
申请人： Dominique BAUM , Gerhard-Wilhelm Bielenberg , Bernd Boedecker , Dirk Thormaehlen
发明人： Dominique BAUM , Gerhard-Wilhelm Bielenberg , Bernd Boedecker , Dirk Thormaehlen
IPC分类号： A61K9/30 , A61K31/513 , A61K31/421 , A61K31/4184 , A61K31/4178 , A61K31/41 , A61K9/20 , A61K9/28 , A61K31/5415 , A61P3/06 , A61P3/00 , A61P3/10 , A61P9/04 , A61P13/12 , A61P9/12 , A61P7/10
CPC分类号： A61K45/06 , A61K31/4178 , A61K31/506 , A61K2300/00
摘要： Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.
摘要翻译：包含与血管紧张素II受体阻断剂联合的选择性咪唑啉受体激动剂的药物组合物，特别是含有莫索尼定和甲磺酸依普罗沙坦的药物组合物，以及这些组合物用于治疗高血压的用途，特别是在患有II型糖尿病的高血压患者中发展II型糖尿病。

2. 发明申请

US20050143435A1 Pharmaceutical compositions comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker 审中-公开
标题翻译：包含选择性I 1咪唑啉受体激动剂和血管紧张素II受体阻断剂的药物组合物
公开(公告)号：US20050143435A1
公开(公告)日：2005-06-30
申请号：US10959317
申请日：2004-10-07
申请人： Dominique Baum , Gerhard-Wilhelm Bielenberg , Bernd Boedecker , Dirk Thormaehlen
发明人： Dominique Baum , Gerhard-Wilhelm Bielenberg , Bernd Boedecker , Dirk Thormaehlen
IPC分类号： A61K31/4172 , A61K31/4178 , A61K31/4184 , A61K31/506 , A61K45/06
CPC分类号： A61K45/06 , A61K31/4178 , A61K31/506 , A61K2300/00
摘要： Parmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.
摘要翻译：包含与血管紧张素II受体阻断剂组合的选择性咪唑啉受体激动剂的药物组合物，特别是包含莫西尼定和甲磺酸依普罗沙坦的药物组合物，以及这些组合物用于治疗高血压的用途，特别是在患有II型糖尿病的高血压患者中发展II型糖尿病。

3. 发明授权

US5532251A Method of treating cardiac arrhythmia with 3-benzoyl-3, 7-diazabicyclo[3.3.1]nonane compounds 失效
标题翻译：用3-苯甲酰基-3,7-二氮杂双环[3.3.1]壬烷化合物治疗心律失常的方法
公开(公告)号：US5532251A
公开(公告)日：1996-07-02
申请号：US382265
申请日：1995-02-01
申请人： Uwe Schoen , Reinhard Brueckner , Joerg Meil , Dirk Thormaehlen
发明人： Uwe Schoen , Reinhard Brueckner , Joerg Meil , Dirk Thormaehlen
IPC分类号： C07D471/18 , A61K31/439 , A61K31/445 , A61K31/495 , C07D471/08 , C07D471/10 , C07D487/10 , A61K31/44
CPC分类号： C07D487/10 , A61K31/495 , Y10S514/821
摘要： The use of 3-benzoyl-3,7-diazabicyclo[3.3.1]nonane compounds of the general formula I ##STR1## in which R.sup.1 is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms,R.sup.2 and R.sup.3 are each individually lower alkyl or together form an alkylene chain having 3-6 carbon atoms,R.sup.4 is hydrogen, halogen, cyano, nitro, trifluoromethyl or a R.sup.6 --SO.sub.2 -- group, in which R.sup.6 is fluorine or lower alkyl, andR.sup.5 is hydrogen, halogen, trifluoromethyl or nitro, or their physiologically acceptable acid addition salts for the treatment of cardiac arrhythmias in larger mammals, including humans.
摘要翻译：使用通式I的3-苯甲酰基-3,7-二氮杂双环[3.3.1]壬烷化合物，其中R 1是具有1-6个碳原子的烷基或具有4-7个碳原子的环烷基烷基原子，R2和R3各自为低级烷基或一起形成具有3-6个碳原子的亚烷基链，R4为氢，卤素，氰基，硝基，三氟甲基或R6-SO2-基，其中R6为氟或低级烷基 R5为氢，卤素，三氟甲基或硝基，或其生理上可接受的酸加成盐，用于治疗包括人在内的较大哺乳动物心律失常。

4. 发明申请

US20050288272A1 Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists 审中-公开
标题翻译：包含NEP-抑制剂，内源性内皮素产生系统的抑制剂和AT1受体拮抗剂的药物组合物
公开(公告)号：US20050288272A1
公开(公告)日：2005-12-29
申请号：US11155782
申请日：2005-06-20
申请人： Dieter Ziegler , Klaus Witte , Matthias Straub , Yvan Fischer , Dirk Thormaehlen , Dagmar Hoeltje
发明人： Dieter Ziegler , Klaus Witte , Matthias Straub , Yvan Fischer , Dirk Thormaehlen , Dagmar Hoeltje
IPC分类号： A61K31/55
CPC分类号： A61K45/06 , A61K31/55 , A61K2300/00
摘要： A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.
摘要翻译：一种用于心血管疾病，特别是原发性高血压，肺动脉高压和/或充血性心力衰竭的联合疗法，包括施用至少一种中性内肽酶抑制剂，至少一种内源性内皮素产生系统的抑制剂和至少一种 AT 1受体拮抗剂。

5. 发明授权

US06482820B2 Pharmaceutical compositions and method for the inhibition and treatment of secondary hypertension 有权
标题翻译：用于抑制和治疗继发性高血压的药物组合物和方法
公开(公告)号：US06482820B2
公开(公告)日：2002-11-19
申请号：US09930186
申请日：2001-08-16
申请人： Martin R. Wilkins , Dirk Thormaehlen , Harald Waldeck
发明人： Martin R. Wilkins , Dirk Thormaehlen , Harald Waldeck
IPC分类号： A61K3155
CPC分类号： A61K31/55
摘要： The present invention relates to the use of benzazepine-N-acetic acid derivatives which contain an oxo-group in the &agr;-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclo-entylcarbonylamino radical, and their salts and biolabile esters for the treatment of hypertension, particularly for the treatment of certain forms of secondary hypertension, in larger mammals and particularly humans, and for the production of pharmaceutical compositions suitable for this treatment. The cause of the hypertension to be treated may have a wide variety of origins. The invention particularly relates to the treatment of those forms of secondary hypertension which may occur as a result of various non-cardiac diseases.
摘要翻译：本发明涉及苯并氮杂-N-乙酸衍生物在氮原子的α-位上含有氧基并在3位被1-（羧基烷基）环 - 羰基羰基取代的用途，盐和生物不稳定酯，用于治疗高血压，特别是用于治疗某些形式的继发性高血压，在较大的哺乳动物，特别是人类中，以及用于生产适用于该治疗的药物组合物。治疗高血压的原因可能有多种多样的起源。本发明特别涉及可能由于各种非心脏疾病而发生的那些形式的继发性高血压的治疗。

6. 发明申请

US20100203132A1 Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and AT1 Receptor Antagonists 审中-公开
标题翻译：包含NEP抑制剂，内源性内皮素产生抑制剂和AT1受体拮抗剂的药物组合物
公开(公告)号：US20100203132A1
公开(公告)日：2010-08-12
申请号：US12764518
申请日：2010-04-21
申请人： Dieter Ziegler , Klaus Witte , Matthias Straub , Yvan Fischer , Dirk Thormaehlen , Dagmar Hoeltje
发明人： Dieter Ziegler , Klaus Witte , Matthias Straub , Yvan Fischer , Dirk Thormaehlen , Dagmar Hoeltje
IPC分类号： A61K31/55 , A61K31/616 , A61K9/28 , A61P9/04 , A61P9/12 , B65D71/00
CPC分类号： A61K45/06 , A61K31/55 , A61K2300/00
摘要： A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.
摘要翻译：一种用于心血管疾病，特别是原发性高血压，肺动脉高压和/或充血性心力衰竭的联合疗法，包括施用至少一种中性内肽酶抑制剂，至少一种内源性内皮素产生系统的抑制剂和至少一种 AT1受体拮抗剂。

7. 发明授权

US07273860B2 Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients 失效
标题翻译：用于治疗或抑制肾功能异常，疾病或病症，特别是糖尿病患者的方法和药物组合物
公开(公告)号：US07273860B2
公开(公告)日：2007-09-25
申请号：US10988847
申请日：2004-11-16
申请人： Dirk Thormaehlen , Berthold Hocher , Harald Waldeck
发明人： Dirk Thormaehlen , Berthold Hocher , Harald Waldeck
IPC分类号： A61K31/55
CPC分类号： A61K31/55
摘要： Treatment and/or inhibition of renal dysfunction, disease or disorder in larger mammals, and particularly in humans, especially in human patients suffering from diabetes, using benzazepine-N-acetic acid derivatives which contain an oxo-group in the α-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclopentylcarbonylamino radical, and/or salts or biolabile esters or physiologically acceptable solvates thereof, and production of pharmaceutical compositions and products suitable for treatment and/or inhibition of renal dysfunction, disease or disorder, particularly in diabetic patients, but also in patients with syndrome X or in patients with a renal dysfunction, disease and/or disorder, which patients are additionally hypertensive, obese, hyperglycemic and/or subject to a metabolic disorder.
摘要翻译：在大型哺乳动物，特别是人，特别是患有糖尿病的人类患者中，使用含有氧代基的苯并氮杂-N-乙酸衍生物，在α位置的治疗和/或抑制肾功能障碍，疾病或病症氮原子，并且在3位上被1-（羧基烷基）环戊基羰基氨基取代，和/或其盐或生物不稳定酯或其生理学上可接受的溶剂合物，以及适于治疗和/或抑制肾功能障碍的药物组合物和产品的生产或障碍，特别是在糖尿病患者中，而且在患有综合征X或患有肾功能障碍，疾病和/或障碍的患者中，该患者另外是高血压，肥胖，高血糖和/或经历代谢紊乱。

8. 发明申请

US20050137183A1 Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients 失效
标题翻译：用于治疗或抑制肾功能异常，疾病或病症，特别是糖尿病患者的方法和药物组合物
公开(公告)号：US20050137183A1
公开(公告)日：2005-06-23
申请号：US10988847
申请日：2004-11-16
申请人： Dirk Thormaehlen , Berthold Hocher , Harald Waldeck
发明人： Dirk Thormaehlen , Berthold Hocher , Harald Waldeck
IPC分类号： A61K31/55
CPC分类号： A61K31/55
摘要： Treatment and/or inhibition of renal dysfunction, disease or disorder in larger mammals, and particularly in humans, especially in human patients suffering from diabetes, using benzazepine-N-acetic acid derivatives which contain an oxo-group in the α-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclopentylcarbonylamino radical, and/or salts or biolabile esters or physiologically acceptable solvates thereof, and production of pharmaceutical compositions and products suitable for treatment and/or inhibition of renal dysfunction, disease or disorder, particularly in diabetic patients, but also in patients with syndrome X or in patients with a renal dysfunction, disease and/or disorder, which patients are additionally hypertensive, obese, hyperglycemic and/or subject to a metabolic disorder.
摘要翻译：在大型哺乳动物，特别是人，特别是患有糖尿病的人类患者中，使用含有氧代基的苯并氮杂-N-乙酸衍生物，在α位置的治疗和/或抑制肾功能障碍，疾病或病症氮原子，并且在3位上被1-（羧基烷基）环戊基羰基氨基取代，和/或其盐或生物不稳定酯或其生理学上可接受的溶剂合物，以及适于治疗和/或抑制肾功能障碍的药物组合物和产品的生产或障碍，特别是在糖尿病患者中，而且在患有综合征X或患有肾功能障碍，疾病和/或病症的患者中，该患者另外是高血压，肥胖，高血糖和/或经历代谢紊乱。

9. 发明授权

US5952327A Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives process for their preparation and pharmaceutical compositions comprising them 有权
标题翻译：膦酸取代的苯并氮杂-乙酸衍生物的制备方法和包含它们的药物组合物
公开(公告)号：US5952327A
公开(公告)日：1999-09-14
申请号：US189796
申请日：1998-11-12
申请人： Harald Waldeck , Joerg Meil , Dirk Thormaehlen , Michael Wurl
发明人： Harald Waldeck , Joerg Meil , Dirk Thormaehlen , Michael Wurl
IPC分类号： A61K31/675 , A61K31/00 , A61K31/55 , A61K38/00 , A61P9/00 , A61P9/04 , A61P9/12 , C07D223/16 , C07F9/38 , C07F9/40 , C07F9/553 , C07K5/06 , C07D223/32
CPC分类号： C07K5/06191 , A61K38/00 , Y02P20/55
摘要： Compounds having NEP-inhibitory activity, corresponding to the formula I in whichR.sup.1 is hydrogen or a group forming a biolabile phosphonic acid ester,R.sup.2 is hydrogen or a group forming a biolabile phosphonic acid ester andR.sup.3 is hydrogen or a group forming a biolabile carboxylic acid esterand physiologically acceptable salts of acids of formula I, and pharmaceutical compositions comprising these compounds.
摘要翻译：具有NEP-抑制活性的化合物，其对应于其中R 1是氢的式I或形成可生物不稳定的膦酸酯的基团，R 2是氢或形成可生物不稳定的膦酸酯的基团，并且R 3是氢或形成生物不稳定羧酸的基团酸酯和式I的酸的生理上可接受的盐，以及包含这些化合物的药物组合物。

10. 发明授权

US5783573A Pharmaceuticals which promote gastrointestinal blood circulation 失效
标题翻译：促进胃肠道血液循环的药物
公开(公告)号：US5783573A
公开(公告)日：1998-07-21
申请号：US929114
申请日：1997-09-15
申请人： Susanna Rozsa , Julius Gy. Papp , Dirk Thormaehlen , Harald Waldeck
发明人： Susanna Rozsa , Julius Gy. Papp , Dirk Thormaehlen , Harald Waldeck
IPC分类号： C07D223/16 , A61K31/55 , A61P1/00
CPC分类号： A61K31/55
摘要： The use is described of compounds of the general formula I ##STR1## wherein R.sup.1 represents a phenyl-lower alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or represents a naphthyl-lower alkyl group, R.sup.2 denotes hydrogen or a biolabile ester-forming group, and R.sup.3 denotes hydrogen or a biolabile ester-forming group, and physiologically acceptable salts of the acids of formula I for preparing pharmaceutical compositions for the treatment and/or prophylaxis of gastrointestinal blood circulation disturbances.
摘要翻译：描述了通式I的化合物，其中R 1表示苯基 - 低级烷基，其可以在苯环中被低级烷基，低级烷氧基或卤素任意取代，或表示萘基 - 低级烷基， R2表示氢或不生物不稳定酯形成基团，R 3表示氢或不可生物酯形成基团，以及用于制备用于治疗和/或预防胃肠道血液循环障碍的药物组合物的式I的酸的生理学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式